• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Akoya BioSciences Inc.

    8/28/24 10:45:17 AM ET
    $AKYA
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $AKYA alert in real time by email
    SC 13G 1 bwls-akya123123.htm



     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. )*



    Akoya Biosciences, Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.00001 per share

    (Title of Class of Securities)

     

    00974H104

    (CUSIP Number)

     

     

    December 31, 2023
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    o Rule 13d-1(b)

    x Rule 13d-1(c)

    o Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     


     

    CUSIP No.  00974H104
     SCHEDULE 13G
    Page 2 of 10 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Blue Water Life Science Advisors, LP
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    4,697,785
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    4,697,785
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    4,697,785
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    9.56%
    12
    TYPE OF REPORTING PERSON
     
    IA

     


     

    CUSIP No.  00974H104
     SCHEDULE 13G
    Page 3 of 10 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Blue Water Life Science Master Fund, Ltd.
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Cayman Islands
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    4,697,785
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    4,697,785
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    4,697,785
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    9.56%
    12
    TYPE OF REPORTING PERSON
     
    OO

     


     

    CUSIP No.  00974H104
     SCHEDULE 13G
    Page 4 of 10 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
      Nathaniel T. Cornell
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States of America
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    4,697,785
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    4,697,785
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    4,697,785
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    9.56%
    12
    TYPE OF REPORTING PERSON
     
    IN
     


     

    CUSIP No.  00974H104
     SCHEDULE 13G
    Page 5 of 10 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
     Blue Water Life Science, LP

    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    4,697,785
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    4,697,785
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    4,697,785
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    9.56%
    12
    TYPE OF REPORTING PERSON
     
    PN
     


     

     

    CUSIP No. 00974H104
     SCHEDULE 13G
    Page 6 of 10 Pages

     

    Item 1.(a) Name of Issuer

    Akoya Biosciences, Inc.

    Item 1.(b) Address of Issuer’s Principal Executive Offices

    100 Campus Drive, 6th Floor Marlborough,

    Massachusetts 01752

    Item 2.

     

     

     

     

     

     

     

     

     

     

     Item 2.

     

     

     

     

     

     

     

     

     

     

     

     

     

    Item 2.

     

    (a) Names of Person Filing:

     

      (i) Blue Water Life Science Advisors, LP

     

     (ii) Blue Water Life Science Master Fund, Ltd.

     

    (iii) Nathaniel T. Cornell

     

    (iv)  Blue Water Life Science, LP

     

     

    (b) Address of Principal Business Office:

     

     (i) 80 E. Sir Francis Drake Blvd. Suite 4A

          Larkspur, California 94939

     

    (ii)  4th PL, Harbour Place 103 S Church St

           Grand Cayman, Cayman Islands KYI-1002

     

    (iii) 80 E. Sir Francis Drake Blvd. Suite 4A

           Larkspur, California 94939

     

    (iv) 80 E. Sir Francis Drake Blvd. Suite 4A

           Larkspur, California 94939

     

    (c) Citizenship:

     

     (i) Delaware

      

     (ii)  Cayman Islands

     

    (iii) United States of America

     

    (iv) Delaware

     

      

    Item 2.(d) Title of Class of Securities

    Common Stock, par value $0.00001 per share (the “Common Stock”)

     

    Item 2.(e) CUSIP No.:

    00974H104

     

    CUSIP No.  00974H104
     SCHEDULE 13G
    Page 7 of 10 Pages

     

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

      (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
     
      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
     
      (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
     
      (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
     
      (e) o An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
     
      (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
     
      (g) ¨ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
     
      (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
     
      (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
     
      (j) ¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
     
      (k) ¨ A group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:                            
           

     

    CUSIP No. 00974H104
     SCHEDULE 13G
    Page 8 of 10 Pages

     

     

    Item 4. Ownership

    Information with respect to the Reporting Persons' ownership of the Common Stock as of December 31, 2023 is incorporated by reference to items (5) - (9) and (11) of the cover page of the respective Reporting Person.

    The amount beneficially owned by each Reporting Person is determined based on 49,117,738 shares of Common Stock outstanding as of December 31, 2023, as the Issuer reported in its Form 10-K filed with the SEC on March 5, 2024.

    Item 5. Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person

    Not Applicable.

    Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

    Not Applicable.

    Item 8. Identification and Classification of Members of the Group

    Not Applicable.

    Item 9. Notice of Dissolution of Group 

    Not Applicable.

    Item 10. Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     
    CUSIP No. 00974H104
     SCHEDULE 13G
    Page 9 of 10 Pages

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: August 28, 2024

     

     

     

     

    Blue Water Life Science Advisors, LP

    By:  Entity and Description

           
      By:  /s/ Nathaniel T. Cornell
        Nathaniel T. Cornell, Managing Member
           
     

    Blue Water Life Science Master Fund, Ltd.

    By:  Entity and Description

           
      By:  /s/ Nathaniel T. Cornell
        Nathaniel T. Cornell, Managing Member
           
     

    Nathaniel T. Cornell

    By:  Entity and Description

           
      By:  /s/ Nathaniel T. Cornell
        Nathaniel T. Cornell
           
     

    Blue Water Life Science, LP

    By:  Entity and Description

           
      By:  /s/ Nathaniel T. Cornell
        Nathaniel T. Cornell, Managing Member
           

     

     
    CUSIP No. 00974H104
     SCHEDULE 13G
    Page 10 of 10 Pages

     

    Exhibit I

     

    JOINT FILING STATEMENT

     

    PURSUANT TO RULE 13d-1(k)

     

    The undersigned acknowledge and agree that the foregoing statement on Schedule 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

     

    Dated: August 28, 2024

     

     

    Blue Water Life Science Advisors, LP

           
      By:  /s/ Nathaniel T. Cornell
        Nathaniel T. Cornell, Managing Member
           
     

    Blue Water Life Science Master Fund, Ltd.

           
      By:  /s/ Nathaniel T. Cornell
        Nathaniel T. Cornell, Managing Member
           
     

    Nathaniel T. Cornell

           
      By:  /s/ Nathaniel T. Cornell
        Nathaniel T. Cornell
           
     

    Blue Water Life Science, LP

           
      By:  /s/ Nathaniel T. Cornell
        Nathaniel T. Cornell, Managing Member
    Get the next $AKYA alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $AKYA

    DatePrice TargetRatingAnalyst
    11/15/2024$7.00 → $5.00Buy → Hold
    Craig Hallum
    8/6/2024Overweight → Equal-Weight
    Morgan Stanley
    8/6/2024Buy → Neutral
    BTIG Research
    8/6/2024Overweight → Neutral
    JP Morgan
    6/21/2024$7.50Buy
    Craig Hallum
    12/14/2023Neutral
    Guggenheim
    7/5/2023$18.00Overweight
    JP Morgan
    2/2/2023$14.00Buy
    UBS
    More analyst ratings

    $AKYA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Akoya Biosciences downgraded by Craig Hallum with a new price target

      Craig Hallum downgraded Akoya Biosciences from Buy to Hold and set a new price target of $5.00 from $7.00 previously

      11/15/24 8:33:16 AM ET
      $AKYA
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Akoya Biosciences downgraded by Morgan Stanley

      Morgan Stanley downgraded Akoya Biosciences from Overweight to Equal-Weight

      8/6/24 12:17:30 PM ET
      $AKYA
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Akoya Biosciences downgraded by BTIG Research

      BTIG Research downgraded Akoya Biosciences from Buy to Neutral

      8/6/24 6:28:51 AM ET
      $AKYA
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $AKYA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Kent Lake Responds to Quanterix's Post-Effective Amendment and Akoya's Superior $1.40-per-Share Alternative Proposal

      RINCON, Puerto Rico, May 23, 2025 /PRNewswire/ -- Kent Lake PR LLC ("Kent Lake"), a holder of approximately 6.9% of the outstanding common stock of Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), today issued the following statement regarding the Company's Post-Effective Amendment to its S-4 registration statement and Akoya Biosciences' ("Akoya") (NASDAQ:AKYA) disclosure of an unsolicited all-cash offer at $1.40-per-share. "Quanterix's amended merger terms (the "Amended Merger Agreement"), structured to avoid a shareholder vote, already commit the company to pay $20 million in cash alongside 8.4 million newly issued shares in its misguided pursuit of Akoya. On May 20, 20

      5/23/25 2:21:00 PM ET
      $AKYA
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Akoya Biosciences Reports First Quarter 2025 Financial Results

      MARLBOROUGH, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA) ("Akoya"), The Spatial Biology Company®, today announced its financial results for the first quarter ending March 31, 2025. "Akoya remained focused on operational discipline and innovation in the first quarter of 2025, while successfully increasing our installed base in the face of broader macroeconomic and NIH funding uncertainty. Our technology continues to gain momentum globally, underscored by growing adoption in large-scale population studies as well as an expanding publication footprint across key research areas in high-impact journals," said Brian McKelligon, CEO of Akoya Biosciences. "As we

      5/12/25 4:05:00 PM ET
      $AKYA
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Kent Lake Issues Statement on Quanterix's Blatant Disregard for Will of Shareholders

      It is Deeply Disturbing, in Kent Lake's View, that the Company's Amended Agreement to Merge with Akoya Deprives Quanterix Shareholders of Ability to Vote on the Transaction Believes Quanterix's Maneuvers Further Demonstrate the Need for New Directors with Real Credibility and Accountability to Shareholders – And Will Press on With Nominations of Three Highly Qualified Board Candidates Kent Lake PR LLC ("Kent Lake"), a holder of approximately 7.7% of the outstanding common stock of Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), today issued the following statement regarding the Company's announcement of an amended merger agreement (the "Amended Merger Agreement") relat

      4/30/25 8:00:00 AM ET
      $AKYA
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $AKYA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Clinical Officer Bamford Pascal covered exercise/tax liability with 670 shares, decreasing direct ownership by 0.32% to 205,738 units (SEC Form 4)

      4 - Akoya Biosciences, Inc. (0001711933) (Issuer)

      6/2/25 5:52:39 PM ET
      $AKYA
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • CFO Ek John Frederick covered exercise/tax liability with 16,432 shares, decreasing direct ownership by 6% to 248,202 units (SEC Form 4)

      4 - Akoya Biosciences, Inc. (0001711933) (Issuer)

      4/3/25 5:14:37 PM ET
      $AKYA
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • President and CEO Mckelligon Brian covered exercise/tax liability with 7,550 shares, decreasing direct ownership by 2% to 420,126 units (SEC Form 4)

      4 - Akoya Biosciences, Inc. (0001711933) (Issuer)

      3/25/25 6:34:07 PM ET
      $AKYA
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $AKYA
    SEC Filings

    See more
    • SEC Form DEFM14A filed by Akoya BioSciences Inc.

      DEFM14A - Akoya Biosciences, Inc. (0001711933) (Filer)

      6/16/25 11:03:33 AM ET
      $AKYA
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form 425 filed by Akoya BioSciences Inc.

      425 - Akoya Biosciences, Inc. (0001711933) (Subject)

      6/4/25 4:01:16 PM ET
      $AKYA
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Akoya BioSciences Inc. filed SEC Form 8-K: Other Events

      8-K - Akoya Biosciences, Inc. (0001711933) (Filer)

      6/2/25 4:05:19 PM ET
      $AKYA
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $AKYA
    Leadership Updates

    Live Leadership Updates

    See more
    • Akoya Biosciences Announces Leadership Transition

      Joe Driscoll to Retire After More than Four Successful Years as Chief Financial Officer Johnny Ek Appointed as new Chief Financial Officer MARLBOROUGH, Mass., March 20, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA) ("Akoya"), The Spatial Biology Company®, today announced that Chief Financial Officer Joe Driscoll is retiring from his position, effective March 20, 2023. Johnny Ek has been appointed as the company's new Chief Financial Officer, effective immediately. Mr. Driscoll will continue to serve as a consultant of the company as Akoya executes a seamless transition between the two leaders. Mr. Driscoll joined Akoya in April 2019 and has overseen the company's financ

      3/20/23 4:00:00 PM ET
      $AKYA
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Akoya Biosciences Announces Appointment of Jennifer Kamocsay as General Counsel

      MARLBOROUGH, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA) ("Akoya"), The Spatial Biology Company®, today announced the appointment of Jennifer Kamocsay as General Counsel. Ms. Kamocsay will oversee all company legal activities and provide strategic guidance and corporate governance oversight. "We are excited to welcome Jennifer to our leadership team," said Brian McKelligon, Chief Executive Officer of Akoya. "Her deep legal expertise and insight will be invaluable as we continue to advance our spatial biology platform and establish additional partnerships to support discovery, translational, and clinical markets." Ms. Kamocsay most recently served as Gen

      2/28/23 8:00:00 AM ET
      $AKYA
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Akoya Biosciences Announces Ehab A. El-Gabry, MD, as Chief Medical Officer

      MARLBOROUGH, Mass., April 19, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (NASDAQ:AKYA), The Spatial Biology Company®, today announced the appointment of Dr. Ehab A. El-Gabry as the company's Chief Medical Officer (CMO). In this newly created position, Dr. El-Gabry will lead Akoya's strategy in advancing the use of its spatial phenotyping solutions in the clinical setting. Dr. El-Gabry brings a wealth of experiences that are critical to the company's vision of advancing spatial phenotyping in precision medicine and cancer care. He is a board-certified pathologist who served as the Senior Medical Director for Roche Tissue Diagnostics Personalized Health Care Solutions (PHCS). As the

      4/19/22 8:05:00 AM ET
      $AKYA
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $AKYA
    Financials

    Live finance-specific insights

    See more
    • Akoya Biosciences Reports First Quarter 2025 Financial Results

      MARLBOROUGH, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA) ("Akoya"), The Spatial Biology Company®, today announced its financial results for the first quarter ending March 31, 2025. "Akoya remained focused on operational discipline and innovation in the first quarter of 2025, while successfully increasing our installed base in the face of broader macroeconomic and NIH funding uncertainty. Our technology continues to gain momentum globally, underscored by growing adoption in large-scale population studies as well as an expanding publication footprint across key research areas in high-impact journals," said Brian McKelligon, CEO of Akoya Biosciences. "As we

      5/12/25 4:05:00 PM ET
      $AKYA
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Akoya Reports Fourth Quarter of 2024 and Full Year Financial Results

      MARLBOROUGH, Mass., March 17, 2025 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA) ("Akoya"), The Spatial Biology Company®, today announced its financial results for the fourth quarter and full year ending December 31, 2024. "Akoya navigated a challenging 2024 in the life science tools market, which was constrained by subdued capital equipment purchases, by successfully strengthening gross margins, reducing operating expenses and advancing our companion diagnostics programs throughout the year. We remain optimistic about the long-term growth outlook of Akoya's leading spatial biology solutions," said Brian McKelligon, CEO of Akoya. "In 2024, Akoya achieved multiple milestones, i

      3/17/25 4:00:00 PM ET
      $AKYA
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Quanterix to Acquire Akoya Biosciences, Creating the First Integrated Solution for Ultra-Sensitive Detection of Blood- and Tissue-Based Protein Biomarkers

      Complementary offerings will accelerate translation of biomarkers from research to the clinic driving new growth Expanded customer relationships and continuum of solution offerings maximize cross-selling opportunities across translational, academic and pharma applications Expects to generate approximately $40 million of annual cost synergies by the end of 2026 with path to positive free cash flow generation in 2026 Combined cash position of approximately $175 million with no expected debt at closing to pursue future growth initiatives Quanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, and Akoya Biosciences (NASDAQ

      1/10/25 7:00:00 AM ET
      $AKYA
      $QTRX
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $AKYA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Akoya BioSciences Inc.

      SC 13G/A - Akoya Biosciences, Inc. (0001711933) (Subject)

      11/4/24 7:39:24 AM ET
      $AKYA
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G filed by Akoya BioSciences Inc.

      SC 13G - Akoya Biosciences, Inc. (0001711933) (Subject)

      8/28/24 10:45:17 AM ET
      $AKYA
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G/A filed by Akoya BioSciences Inc. (Amendment)

      SC 13G/A - Akoya Biosciences, Inc. (0001711933) (Subject)

      2/14/24 4:09:03 PM ET
      $AKYA
      Biotechnology: Laboratory Analytical Instruments
      Industrials